{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:26Z","timestamp":1794013286581,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xkme.2025.101125","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:42:24Z","timestamp":1758616944000},"page":"101125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury"],"prefix":"10.1016","volume":"7","author":[{"given":"Benjamin J.","family":"Strimaitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-6595","authenticated-orcid":false,"given":"Eoin D.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xkme.2025.101125_bib1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/000331978703801007","article-title":"Cholesterol crystal embolization: a review of 221 cases in the English literature","volume":"38","author":"Fine","year":"1987","journal-title":"Angiology"},{"issue":"6","key":"10.1016\/j.xkme.2025.101125_bib2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1053\/ajkd.2000.19809","article-title":"Cholesterol crystal embolism: A recognizable cause of renal disease","volume":"36","author":"Scolari","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.xkme.2025.101125_bib3","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1053\/j.ajkd.2016.02.034","article-title":"AJKD Atlas of Renal Pathology: Cholesterol Emboli","volume":"67","author":"Lusco","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.xkme.2025.101125_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/000331970505600420","article-title":"Cholesterol embolization treated with corticosteroids: two case reports","volume":"56","author":"Koga","year":"2005","journal-title":"Angiology"},{"issue":"9","key":"10.1016\/j.xkme.2025.101125_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2169\/internalmedicine.52.9255","article-title":"Use of corticosteroids in the treatment of cholesterol crystal embolism after cardiac catheterization: a report of four Japanese cases","volume":"52","author":"Masuda","year":"2013","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.xkme.2025.101125_bib6","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/sj.ki.5000263","article-title":"Cholesterol crystal embolism: diagnosis and treatment","volume":"69","author":"Meyrier","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101125_bib7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1503\/cmaj.090919","article-title":"Cholesterol microembolization syndrome: a complication of anticoagulant therapy","volume":"182","author":"Varis","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.xkme.2025.101125_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1179547616684649","article-title":"Performing anticoagulation: a puzzling case of cholesterol embolization syndrome","volume":"10","author":"Igarashi","year":"2017","journal-title":"Clin Med Insights Case Rep"},{"issue":"4","key":"10.1016\/j.xkme.2025.101125_bib9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5414\/CNP66232","article-title":"Low-dose prednisolone ameliorates acute renal failure caused by cholesterol crystal embolism","volume":"66","author":"Nakayama","year":"2006","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2025.101125_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2169\/internalmedicine.8088-21","article-title":"Use of proprotein converse subtilisin\/kexin type 9 inhibitor to treat cholesterol crystal embolisms after catheterization: a report of three cases","volume":"61","author":"Tomoi","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.xkme.2025.101125_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18773\/austprescr.2016.060","article-title":"PCSK9 inhibitors \u2013 mechanisms of action","volume":"39","author":"Page","year":"2016","journal-title":"Aust Prescr"},{"key":"10.1016\/j.xkme.2025.101125_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"issue":"23","key":"10.1016\/j.xkme.2025.101125_bib13","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.xkme.2025.101125_bib14","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.transproceed.2023.07.020","article-title":"Safe and successful treatment with PCSK9 inhibitors in hypercholesterolemia and renal transplantation: a case report","volume":"55","author":"Garc\u00eda-Agudo","year":"2023","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.xkme.2025.101125_bib15","article-title":"A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease","volume":"14","author":"Igweonu-Nwakile","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.xkme.2025.101125_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/0886022X.2020.1726383","article-title":"Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin\/kexin type 9 (PCSK9) antibody: a case report","volume":"42","author":"Morino","year":"2020","journal-title":"Ren Fail"},{"issue":"1","key":"10.1016\/j.xkme.2025.101125_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.xkme.2025.101125_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol"},{"issue":"22","key":"10.1016\/j.xkme.2025.101125_bib19","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.xkme.2025.101125_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952500161X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952500161X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:58:39Z","timestamp":1763665119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259005952500161X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S259005952500161X"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101125","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101125"}}